| | Webinar: Digitize Remote Site Monitoring with Box Tuesday, October 13 | 2pm ET / 11am PT Fierce Pharma is teaming up with Box to discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing. Accelerate R&D processes across the value chain, maintain GxP compliance and reduce your overall IT footprint. Save Your Spot! |
Trump takes Regeneron's antibodies, Gilead's remdesivir, dexamethasone in first days of COVID-19 hospital stay FDA career experts will handle coronavirus vaccine reviews, commissioner says COVID-19 has forced hospitals to be more careful about their suppliers. Here are some of the lessons learned Quidel nets FDA green light for rapid COVID-19, flu antigen test Biopharma roundup: Regeneron's antibody cocktail slapped with patent suit CommonSpirit Health posts $550M operating revenue loss in fiscal year due to COVID-19 NIH to award $234M to support projects bringing COVID-19 testing to underserved populations Nvidia to build the UK’s fastest supercomputer for AI drug-hunters at GSK, AstraZeneca and more As employers gear up for open enrollment, here are the trends to watch Featured Story | By Kyle Blankenship President Donald J. Trump's medical team is navigating an uncertain COVID treatment course for the nation's now-hospitalized leader. With Trump's symptoms "up and down," his physicians are throwing the kitchen sink at the virus, including a steroid therapy typically reserved for the most dire cases. read more |
| |
|---|
|
Top Stories By Eric Sagonowsky With numerous COVID-19 vaccines in late-stage testing, the FDA may soon face critical decisions on whether the candidates are safe and effective enough for emergency use or widespread distribution. While the agency has come under political pressure during the pandemic, commissioner Stephen Hahn on Monday stressed its procedures are adequate to maintain independence for the forthcoming reviews. read more By Robert King Hospitals have had to more closely scrutinize their PPE vendors and suppliers to ensure there are no disruptions in the supply chain, a practice that will likely continue after COVID-19 ends. read more By Conor Hale Quidel snagged an FDA emergency authorization for what it describes as a rapid “ABC” test—a 15-minute, point-of-care diagnostic for influenza A, influenza B and COVID-19—as experts raise alarms about a potential "twindemic" this winter. It's the latest pandemic move for Quidel, which tripled third-quarter sales thanks to its Sofia-2 antigen test. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner Trump's dexamethasone regimen has sparked concerns over the President's health. Regeneron's decision to provide its experimental antibody to the President was difficult, its CEO said; plus, Regeneron's cocktail now faces a patent suit from Allele Biotechnology. The NIH will spend $234 million to improve testing access. Plus, Quidel won approval for a combo flu-COVID-19 test. read more By Robert King Hospital system CommonSpirit Health reported operating losses of $550 million during its fiscal year that ended in June, as the COVID-19 pandemic continues to roil patient volumes. read more By Conor Hale Through its COVID-19 diagnostic development initiative, the NIH announced it has awarded nearly $234 million to improve access to testing among underserved and vulnerable populations. read more By Conor Hale Through a new partnership with GlaxoSmithKline, AstraZeneca and the U.K.’s National Health Service, the chip maker Nvidia plans to build Great Britain’s most powerful supercomputer—and dedicate it to artificial intelligence research in healthcare. read more By Paige Minemyer With employer open enrollment on the horizon, these are the key trends to watch, according to the Business Group on Health. read more |
